Guerbet Vendor's profile

2014 annual revenue
Dienstag, 10. Februar 2015

2014 annual revenue €411.6M (+ 5.6%) at constant exchange rates> Fourth-quarter revenue : €106.4M, +4.3% at constant exchange rates> Annual profitability target confirmed Villepinte, 10 February 2015 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents for medical imagi...

ANSM approves Lipiodol® Ultra-Fluid for visualization, localization and vectorization of hepatocellular carcinoma during trans-arterial chemoembolization Guerbet (GBT) announces the approval of Lipiodol® Ultra-Fluid by the French National Agency for Medicines and Health Products (ANSM) for s...

Guerbet to Exhibit Recently U.S. Approved Imaging Agents at 100 Year Anniversary of RSNADotarem® (gadoterate meglumine) Injection and Lipiodol® (ethiodized oil) Injection to both be presented at Guerbet booth; Guerbet to present five abstracts Princeton (NJ), Guerbet, a pioneer in the field...

Guerbet Receives FDA’s Drug Shortage Assistance Award Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection Guerbet LLC, USA (September 29, 2014) Princeton (NJ), Guerbet, a pioneer in the field of contrast agents for medical imaging, has received a Dr...

  FlowSens®: a new-generation solution in CT imaging Presented for the first time at the European Congress of Radiology (ECR, Vienna, 7-10 March 2014), this unique, innovative solution enables Guerbet to broaden its range in the field of medical equipment and devices for diagnostic...

Contact Guerbet

Title *
Company / organisation *
Firstname *
Job title *
Lastname *
City *
E-mail *
Country *

All information that you supply is protected by our privacy policy.
In order to provide you with this free service, we may share your business information with companies whose content you choose to view on this website.
By submitting your information you agree to our Terms of Use. - See more at: IMAIOS privacy policy

To feature here :  Get in touch